TY - JOUR
T1 - Neuromyelitis Optica Spectrum Disorders
AU - Akaishi, Tetsuya
AU - Nakashima, Ichiro
AU - Sato, Douglas Kazutoshi
AU - Takahashi, Toshiyuki
AU - Fujihara, Kazuo
N1 - Funding Information:
Dr T. Akaishi reports no disclosures. Dr I. Nakashima has received funding for travel and received speaker honoraria from Mitsubishi Tanabe Pharma Corporation and has received research funding from LSI Medience Corporation and the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Dr D.K. Sato has received a scholarship from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19472), research support from CAPES/Brazil (CSF-PAJT—88887.091277/2014-00), and speaker honoraria from Novartis. Dr T. Takahashi reports no disclosures. Prof K. Fujihara serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Merck Serono, Alexion Pharmaceuticals, Medimmune, and Medical Review; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co, Daiichi Sankyo, and Nihon Pharmaceutical; serves as an editorial board member of Clinical and Experimental Neuroimmunology (2009-present) and an advisory board member of Sri Lanka Journal of Neurology; has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan; and is funded by the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#22229008, 2010-2015; #26293205, 2014-2016) and by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan (2010-present).
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Neuromyelitis optica (NMO) is clinically characterized by severe optic neuritis and transverse myelitis, but recent studies with anti-aquaporin-4-antibody specific to NMO have revealed that the clinical spectrum is wider than previously thought. International consensus diagnostic criteria propose NMO spectrum disorders (NMOSD) as the term to define the entire spectrum including typical NMO, optic neuritis, acute myelitis, brain syndrome, and their combinations. NMOSD is now divided into anti-aquaporin-4-antibody-seropositive NMOSD and -seronegative NMOSD (or unknown serostatus). MR imaging and optical coherence tomography are indispensable in the diagnosis and evaluation of NMOSD. This article reviews the clinical and MR imaging findings of anti-aquaporin-4-antibody-seropositive and anti-myelin oligodendrocyte glycoprotein-antibody-seropositive NMOSD.
AB - Neuromyelitis optica (NMO) is clinically characterized by severe optic neuritis and transverse myelitis, but recent studies with anti-aquaporin-4-antibody specific to NMO have revealed that the clinical spectrum is wider than previously thought. International consensus diagnostic criteria propose NMO spectrum disorders (NMOSD) as the term to define the entire spectrum including typical NMO, optic neuritis, acute myelitis, brain syndrome, and their combinations. NMOSD is now divided into anti-aquaporin-4-antibody-seropositive NMOSD and -seronegative NMOSD (or unknown serostatus). MR imaging and optical coherence tomography are indispensable in the diagnosis and evaluation of NMOSD. This article reviews the clinical and MR imaging findings of anti-aquaporin-4-antibody-seropositive and anti-myelin oligodendrocyte glycoprotein-antibody-seropositive NMOSD.
KW - Anti-aquaporin-4 antibody
KW - Anti-myelin oligodendrocyte glycoprotein antibody
KW - MR imaging
KW - Neuromyelitis optica spectrum disorders
KW - Optical coherence tomography
UR - http://www.scopus.com/inward/record.url?scp=85012893293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012893293&partnerID=8YFLogxK
U2 - 10.1016/j.nic.2016.12.010
DO - 10.1016/j.nic.2016.12.010
M3 - Review article
C2 - 28391784
AN - SCOPUS:85012893293
SN - 1052-5149
VL - 27
SP - 251
EP - 265
JO - Neuroimaging Clinics of North America
JF - Neuroimaging Clinics of North America
IS - 2
ER -